Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus By Reuters
Written by Emily J. Thompson, Senior Investment Analyst
Source: Investing.com
Novo Holdings' Acquisition Plans: Novo Holdings aims to double the size of Catalent, a recently acquired contract drugmaker, over five years, following a $16.5 billion acquisition deal and subsequent sale of manufacturing plants to Novo Nordisk.
Impact of U.S. Manufacturing Focus: With President-elect Donald Trump's anticipated policies favoring U.S. manufacturing, more drugmakers may shift from overseas suppliers to American service providers, potentially benefiting companies like Catalent and Thermo Fisher Scientific.
Analyst Views on TMO
Wall Street analysts forecast TMO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMO is 615.44 USD with a low forecast of 561.00 USD and a high forecast of 675.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
17 Buy
3 Hold
0 Sell
Strong Buy
Current: 624.650
Low
561.00
Averages
615.44
High
675.00
Current: 624.650
Low
561.00
Averages
615.44
High
675.00
About TMO
Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. It also provides purification and filtration technologies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
